Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure

Journal of Human Hypertension volume 24, pages 359–362 (2010)Cite this article

Abstract

The role of uric acid (UA) in human physiology is subject to controversy. Either it is an important radical scavenger, a mostly neutral, waste metabolic product that may cause gout and kidney stones if elevated, or it is involved in the causation of hypertension, vascular and renal diseases. Recently we conducted a clinical trial to determine whether raising the serum UA levels through the oral administration of inosine is well tolerated and may benefit patients with multiple sclerosis. An important aspect of the safety profile is whether raising the serum UA levels elevates blood pressure. During the 1-year trial, blood pressure and serum UA levels were monitored in 16 patients. Both parameters were recorded throughout the trial that included 69 visits by patients at baseline and during the placebo phase as well as 138 visits while receiving inosine treatment. We have observed that although the serum UA levels increased significantly during the inosine treatment phase of the trial, from 4.2±0.8 to 7.1±1.7 mg per 100 ml, blood pressure remained unchanged, averaging 123±15/78±9. Our findings indicate that raising the serum UA levels to upper normal physiological levels for a period of up to 1-year does not influence blood pressure significantly.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Wu XW, Lee CC, Muzny DM, Caskey CT . Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 1989; 86: 9412–9416.

    Article  CAS  Google Scholar 

  2. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery Jr C, Jones P et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 1994; 91: 742–746.

    Article  CAS  Google Scholar 

  3. Rafey MA, Lipkowitz MS, Leal-Pinto E, Abramson RG . Uric acid transport. Curr Opin Nephrol Hypertens 2003; 12: 511–516.

    Article  CAS  Google Scholar 

  4. Beckman JS, Koppenol WH . Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424–C1437.

    Article  CAS  Google Scholar 

  5. Squadrito GL, Pryor WA . Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radical Biol Med 1998; 25: 392–403.

    Article  CAS  Google Scholar 

  6. Whiteman M, Ketsawatsakul U, Halliwell B . A reassessment of the peroxynitrite scavenging activity of uric acid. Ann NY Acad Sci 2002; 962: 242–259.

    Article  CAS  Google Scholar 

  7. Scott GS, Hooper DC . The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 2001; 56: 95–100.

    Article  CAS  Google Scholar 

  8. Spitsin S, Koprowski H . Role of uric acid in multiple sclerosis [review]. Curr Top Microbiol Immunol 2008; 318: 325–342.

    CAS  PubMed  Google Scholar 

  9. Watanabe S, Kang D-K, Feng L, Nakagawa T, Kanellis J, Lan H et al. Uric acid, hominoid evolution, and the pathogenesis in salt sensitivity. Hypertension 2002; 40: 355–360.

    Article  CAS  Google Scholar 

  10. Johnson RJ, Kang DH, Freig D, Kivlighn S, Kanellis J, Watanabe S et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183–1190.

    Article  CAS  Google Scholar 

  11. Mene P, Punzo G . Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens 2008; 26: 2085–2092.

    Article  CAS  Google Scholar 

  12. Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC et al. The treatment of multiple Sclerosis with Inosine. J Altern Complement Med 2009; 15: 619–625.

    Article  Google Scholar 

  13. Eraranta A, Kurra V, Tahvanainen AM, Vehmas TI, Koobi P, Lakkisto P et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens 2008; 26: 1661–1668.

    Article  CAS  Google Scholar 

  14. Mazzali M, Jeremy Hughes J, Kim Y-G, Jefferson A, Kang D-H, Gordon KL et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101–1106.

    Article  CAS  Google Scholar 

  15. Feig DI, Soletsky B, Johnson RJ . Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300: 924–932.

    Article  CAS  Google Scholar 

  16. Forman JP, Choi H, Curhan GC . Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 2007; 18: 287–292.

    Article  CAS  Google Scholar 

  17. Singh AK, Amlal H, Haas PJ, Dringenberg U, Fussell S, Barone SL et al. Fructose-induced hypertension: essential role of chloride and fructose absorbing transporters PAT1 and Glut5. Kidney Int 2008; 74: 438–447.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from Commonwealth of Pennsylvania Department of Health to Biotechnology Foundation Laboratories (to HK) and grant from NIH/NCAM (AT 001301) to DCH.

Author information

Authors and Affiliations

  1. Biotechnology Foundation Laboratories, Thomas Jefferson University, Philadelphia, PA, USA

    S Spitsin, H Koprowski & D C Hooper

  2. Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA

    C E Markowitz & V Zimmerman

  3. Department of Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA

    D C Hooper

Authors
  1. S Spitsin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C E Markowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V Zimmerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Koprowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D C Hooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Spitsin.

Ethics declarations

Competing interests

The authors declared no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spitsin, S., Markowitz, C., Zimmerman, V. et al. Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure. J Hum Hypertens 24, 359–362 (2010). https://doi.org/10.1038/jhh.2009.83

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2009.83

Keywords

This article is cited by

Search

Advanced search

Quick links